Sequentify Appoints Dr. Ravi Majeti as Scientific Advisor

REHOVOT, Israel, July 31, 2025 /PRNewswire/ -- Sequentify is pleased to announce the appointment of Dr. Ravi Majeti, a world-renowned expert in hematologic malignancies, as Scientific Advisor.

Dr. Majeti is the Virginia and D.K. Ludwig Professor of Medicine at Stanford University and Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. A board-certified hematologist, Dr. Majeti is internationally recognized for his pioneering research on leukemia stem cells and the molecular pathogenesis of acute myeloid leukemia (AML). His lab has published extensively on the development of novel therapeutic strategies for hematologic cancers and is supported by major NIH and foundation grants.

"Sequentify's approach to scalable, simplified sequencing is exactly what the field of genomic testing needs," said Dr. Majeti. "I'm excited to support their mission to enable decentralized, high-quality genomic testing for hematologic malignancies and beyond."

Dr. Majeti's deep scientific insight and clinical perspective will be instrumental as Sequentify expands its portfolio of hematology-focused NGS panels and drives adoption across academic and clinical settings.

About Sequentify:

Founded in 2021 as a Weizmann Institute spinoff, Sequentify enables decentralized, population-wide genomic sequencing by providing laboratories with the easiest and quickest solutions available. Their technology facilitates the scaling-up of genomic testing by directly addressing the current pain points in the industry, through sample-prep and software solutions. The company offers panels for oncology and screening applications, and infectious diseases, with a focus on the clinical market. Sequentify is based in Rehovot, Israel. For more information, visit https://www.sequentify.com.

Dr. Majeti's advisory role with Sequentify is in a personal capacity and is independent of his Stanford responsibilities.

Logo: https://mma.prnewswire.com/media/2269535/SEQUENTIFY_Logo.jpg

Media Contact:
Avigayil Simpson
[email protected] 

SOURCE Sequentify ltd.